Target
NOTCH1
4 abstracts
Abstract
Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study.Org: Kanagawa Cardiovascular and Respiratory Center, National Cancer Center Hospital East, Kashiwa, Japan, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Department of Data Sciences, Internal Medicine III, Wakayama Medical University,
Abstract
Molecular profiling as a predictor of treatment response and survival in unresectable pancreatic ductal adenocarcinoma.Org: Beth Israel Deaconess Medical Center, Boston, MA,
Abstract
Whole exome sequencing of sinonasal cancers.Org: The Ohio State University Wexner Medical Center, The Ohio State University - James Cancer Hospital, The Ohio State University-James Cancer Hospital Solove Research Institute, The Ohio State University - James Cancer Hospital and Solove Research Institute, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center,
Abstract
Combinatorial immune biomarkers of efficacy on buparlisib and paclitaxel in patients with SCCHN: BERIL-1 sub-analysis.Org: Adlai Nortye USA Inc., Adlai Nortye Biopharma, Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Hemato-Oncology, University of Milan, and Division of Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy,